Navigation Links
DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
Date:10/25/2012

OSAKA, Japan, October 25, 2012 /PRNewswire/ --

Dainippon Sumitomo Pharma Co., Ltd. ("DSP") (Headquarters: Osaka, Japan) and Takeda Pharmaceutical Company Limited ("Takeda") (Headquarters: Osaka, Japan) today announced that the European Medicines Agency (EMA) has confirmed the acceptance for review of the Marketing Authorization Application (MAA) for an atypical antipsychotic medication lurasidone hydrochloride for the treatment of schizophrenia. The MAA was filed by Takeda Global Research & Development Centre (Europe).

Lurasidone, orally administrated once daily, is an atypical antipsychotic medication discovered and developed by DSP with a unique chemical structure as compared to other existing antipsychotic medicines. Takeda entered into a license agreement with DSP stipulating the joint development and grant of an exclusive commercialization right of the product to Takeda in 26 member states of the European Union (excluding the United Kingdom), and Switzerland, Norway, Turkey and Russia in March 2011.

The MAA submission is based on the data from more than 50 clinical trials involving more than 3,800 lurasidone-treated subjects. In phase 3 clinical trials, in which the efficacy and safety of lurasidone in the treatment of patients with schizophrenia were evaluated, lurasidone demonstrated significantly greater improvement versus placebo in the primary efficacy endpoint [Positive and Negative Syndrome Scale (PANSS)* total score]. The most commonly observed adverse reactions in patients treated with lurasidone were somnolence, akathisia, nausea and parkinsonism. Clinical trials also demonstrated that lurasidone was well-tolerated with minimal impact on weight or metabolic parameters.

"Lurasidone is the DSP Group's core product for overseas expansion, and I am very pleased that we have achieved the important milestone of submitting an MAA in Europe." said Masayo Tada, President and Chief Executive Officer of DSP. "Through the cooper
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited and Dainippon Sumitomo Pharma Co., Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Nycomed, a Takeda Company, Launches Omnaris® Nasal Spray in the UAE for the Treatment of Allergic Rhinitis
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
4. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
6. GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
7. WuXi PharmaTech Announces Third-Quarter 2011 Results
8. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
9. Spherix Announces Third Quarter Financial Results
10. Modern Mobility Aids, Inc. Announces November 30, 2011 Closing of Lumigene Acquisition
11. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... Francisco, CA (PRWEB) August 26, 2014 ... reach USD 8,020.1 million by 2020, according to a ... for personalized medicine and theranostics, and the subsequent introduction ... key factors driving market growth over the next six ... and chronic diseases such as cancer, coupled with disease ...
(Date:8/26/2014)... Aug. 26, 2014 Trovagene, Inc. (NASDAQ: ... Dx Summit; Moving Assays to the Clinic ... Monitoring of Cell Free Tumor DNA in Urine." ... of its Precision Cancer Monitoring (PCM) platform and ... for the detection of tumor DNA mutations from ...
(Date:8/26/2014)... NEW YORK , Aug. 26, 2014  That,s ... life science markets, today announced the formation of a ... strategic content development. The expanded team will combine current ... messaging areas at That,s Nice. ... Strategic Content to lead the team. Tiene was previously ...
Breaking Biology Technology:ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4That's Nice Announces Expanded Offering For Strategic Content And Public Relations 2That's Nice Announces Expanded Offering For Strategic Content And Public Relations 3
... VENTURA, Calif., Dec. 12 VivoMetrics Inc., a ... the,appointment of Howard R. Baker to the position ... Paul Kennedy, who will remain with,the company in ... Baker joins VivoMetrics with over 28 years in ...
... Oral Iclaprim, "Rolling" NDA for Intravenous Iclaprim in cSSSI; Electronic ... First Modules ... Arpida Ltd,(SWX: ARPN) announced today the enrolment and dosing of ... iclaprim in the treatment,of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia,(VAP) ...
... for the First Time on 50 mg/Day Dose for PRISTIQ ... Treatment of ... a division of Wyeth (NYSE: WYE ), announces that ... serotonin-norepinephrine reuptake inhibitor (SNRI), showed,that adult patients who received a ...
Cached Biology Technology:VivoMetrics(R) Appoints Howard R. Baker as New President and Chief Executive Officer 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 2First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 3First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 4First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 2New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 3New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 4New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 5New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo 6
(Date:8/25/2014)... that there are 133 active fires in the North Slave ... in the past 24 hours. Fire danger is moderate to ... , The Birch Lake Complex of fires are in an ... within 30 km north of Fort Providence. Four crews ... Moraine Point this week. Mop-up continues many areas of complex,s ...
(Date:8/25/2014)... The Happy Camp Complex of fires began as a lightning ... consumed 22,670 acres and is 20% contained. There ... present. It consists of many small fires and a ... have been contained and only account for about 100 acres. ... the morning and early afternoon on August 24, keeping fire ...
(Date:8/25/2014)... August 25, 2014 Nearly 1 in 6 adults ... time, the disorder can cause serious complications. Auriculotherapy, ... points on the outer ear, may help in ... between 2007-2013 that evaluated the effectiveness of auriculotherapy ... discussed in a Review article in The ...
Breaking Biology News(10 mins):Happy Camper and July Fire Complexes in California 2
... ANN ARBOR, Mich. The risk of esophageal cancer ... is not as high as many may think, according ... GERD is considered a relative risk for developing esophageal ... Joel Rubenstein, M.D., M.Sc., an investigator with the Department ...
... -- When their razor-sharp mandibles wear out, leaf-cutter ants ... sisters take over cutting, say researchers from two Oregon ... regular publication in the journal Behavioral Ecology and ... of providing for its displaced workers. "This ...
... can dive for anything up to 15 minutes. However, Bob ... blue whales may be able to dive for longer, because ... blood and muscles, so why don,t they? ,The theory was ... lot of energy, says Shadwick. Explaining that the whales feed ...
Cached Biology News:Esophageal cancer risk lower than expected for patients with GERD 2When their tools get dull, leaf-cutters switch jobs 2When their tools get dull, leaf-cutters switch jobs 3Blue whale-sized mouthfuls make foraging super efficient 2
... The Dodeca silver stain kits are ... devices including Bio-Rad Dodeca stainers. This ... quantities of proteins in polyacrylamide gels ... kit includes sensitizer concentrate, silver reagent ...
The AVR9-8 stream-select valve is a 9-port, 8-position valve for use with the BioLogic DuoFlow system. This valve is used for high-pressure stream selection....
... stain for staining RNA (bluish-purple), DNA (blue), proteins (red) ... ≥ 90 % Cation traces: Ca ≤ 10 mg/kg ... ≤ 5 mg/kg Cu ≤ 5 mg/kg Fe ≤ ... mg/kg Mn ≤ 5 mg/kg Na ≤ 50 mg/kg ...
... Biometras Tpersonal thermocycler provides maximum performance ... generation of Peltier elements, high heating and ... to short run times. With a maximum ... Tpersonal provides half the capacity of much ...
Biology Products: